Biotech and Pharmaceuticals
Eli Lilly plans at least $27 billion in new U.S. manufacturing investments
A sign with the company logo sits outside of the headquarters of Eli Lilly in Indianapolis, Indiana, on March 17, 2024. Scott Olson | Getty Images Eli Lilly on Wednesday said it will invest at least $27 billion to build four new manufacturing sites in the U.S., as demand for its blockbuster weight loss and diabetes […]
Read More
Healthy Returns: HHS Secretary RFK Jr. is making early moves that may affect vaccine access
Robert F. Kennedy Jr., U.S. President Trump’s nominee to be Secretary of Health and Human Services, testifies before a Senate Finance Committee confirmation hearing on Capitol Hill in Washington, U.S., Jan. 29, 2025. Nathan Howard | Reuters A version of this article first appeared in CNBC’s Healthy Returns newsletter, which brings the latest health-care news […]
Read More
Eli Lilly is selling higher-dose vials of Zepbound at a lower price to boost weight loss drug access
An injection pen of Zepbound, Eli Lilly’s weight loss drug, is displayed in New York City on Dec. 11, 2023. Brendan McDermid | Reuters Eli Lilly on Tuesday released higher doses of its weight loss drug Zepbound in single-dose vials at as much as half its usual monthly list price to reach more patients without […]
Read More
Shortage of Novo Nordisk’s Wegovy and Ozempic drugs is resolved, FDA says
Boxes of Ozempic and Wegovy made by Novo Nordisk are seen at a pharmacy. Hollie Adams | Reuters The long-running U.S. shortage of Novo Nordisk‘s blockbuster weight loss injection Wegovy and diabetes treatment Ozempic is resolved after more than two years, the Food and Drug Administration said on Friday. The FDA’s decision will threaten the […]
Read More
Shortage of Novo’s Wegovy and Ozempic is resolved, FDA website shows
Weight loss syringes of the brands “Wegovy”, “Ozempic” and “Mounjaro” are sold at In der Achat Apotheke in Mitte, Germany. Picture Alliance | Picture Alliance | Getty Images A shortage of Danish drugmaker Novo Nordisk’s popular weight-loss and diabetes drugs, Wegovy and Ozempic, has been resolved, the U.S. Food and Drug Administration’s website showed on […]
Read More
UnitedHealth’s rough stretch continues, with buyouts, a reported DOJ probe and a 23% drop in three months
FILE PHOTO: The logo of Down Jones Industrial Average stock market index listed company UnitedHealthcare is shown in Cypress, California April 13, 2016. Mike Blake | Reuters UnitedHealthcare is in hot water again as the insurance giant grapples with a reported government investigation of its Medicare billing practices, pursues employee buyouts and potential layoffs and […]
Read More
From pills to new uses, here’s what Eli Lilly’s top scientist sees as the future of weight loss drugs
Dan Skovronsky knows what makes a good obesity drug. As chief scientific officer at Eli Lilly, he’s already done it once with the company’s weekly shot, Zepbound. He’s trying to do it again with a more convenient daily pill, then repeat the feat with a shot that could be even more powerful than Zepbound. And […]
Read More
Healthy Returns: Ozempic helps curb alcohol use in new study — and doctors are concerned about telehealth GLP-1s
Steve Christo | Corbis News | Getty Images A version of this article first appeared in CNBC’s Healthy Returns newsletter, which brings the latest health-care news straight to your inbox. Subscribe here to receive future editions. Novo Nordisk‘s blockbuster diabetes drug Ozempic may also help people drink less alcohol. That’s according to new government-funded research […]
Read More
UnitedHealthcare is offering buyouts to employees in benefits unit, could pursue layoffs, sources say
A general view outside the United Healthcare corporate headquarters on December 4, 2024 in Minnetonka, Minnesota. Stephen Maturen | Getty Images UnitedHealthcare is offering certain employees in its benefits operations unit the option to accept buyouts if they quit by March 3, following a tumultuous year for the insurance giant, CNBC has learned. Those who […]
Read More
Moderna beats on revenue but loses more than expected as it scales down manufacturing
Moderna on Friday posted fourth-quarter revenue that beat estimates, but lost more than expected for the period, as the biotech company continues to slash costs and demand for its Covid vaccine falls. It marks another quarter of growing pains for the company, which is racing to launch new products and recover from the rapid decline […]
Read More